Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia-Reference-Cited by-同舟云学术

Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

Published:2017-11-07 Issue:4 Volume:60 Page:1477-1487
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Handels Ron L.H.¹²,Wimo Anders²,Dodel Richard³,Kramberger Milica G.²⁴,Visser Pieter Jelle¹⁵,Molinuevo José Luis⁶⁷,Verhey Frans R.J.¹,Winblad Bengt²

Affiliation:

1. Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands

2. Department of Neurobiology, Care Science and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institute, Huddinge, Sweden

3. Department of NeuroGeriatrics, University Duisburg-Essen, Essen, Germany

4. Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia

5. Department of Neurology and Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands

6. Alzheimer Disease and Other Cognitive Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain

7. Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference28 articles.

1. EFNS guidelines for the diagnosis and management of Alzheimer’s disease;Hort;Eur J Neurol,2010

2. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Jack;Alzheimers Dement,2011

3. Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria;Dubois;Lancet Neurol,2007

4. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria;Dubois;Lancet Neurol,2014

5. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Albert;Alzheimers Dement,2011

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tendencias de la evidencia científica de las evaluaciones económicas y las enfermedades no transmisibles: un análisis bibliométrico;Revista Med;2023-12-29

2. Structural and Functional Retinal Changes in Patients with Mild Cognitive Impairment with and without Diabetes;Journal of Clinical Medicine;2023-11-10

3. Health economic analysis of the integrated cognitive assessment tool to aid dementia diagnosis in the United Kingdom;Frontiers in Public Health;2023-09-29

4. Everyday Driving and Plasma Biomarkers in Alzheimer’s Disease: Leveraging Artificial Intelligence to Expand Our Diagnostic Toolkit;Journal of Alzheimer's Disease;2023-04-18

5. Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis;Journal of Neurology, Neurosurgery & Psychiatry;2022-09-12